A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H

CONTEXT: Pazopanib is a small molecule inhibitor of kinases principally including vascular endothelial growth factor receptors-1, -2, and -3; platelet-derived growth factor receptors-α and -β; and c-Kit. We previously reported a tumor response rate of 49% in patients with advanced differentiated thy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bible, Keith C., Suman, Vera J., Molina, Julian R., Smallridge, Robert C., Maples, William J., Menefee, Michael E., Rubin, Joseph, Karlin, Nina, Sideras, Kostandinos, Morris, John C., McIver, Bryan, Hay, Ian, Fatourechi, Vahab, Burton, Jill K., Webster, Kevin P., Bieber, Carolyn, Traynor, Anne M., Flynn, Patrick J., Cher Goh, Boon, Isham, Crescent R., Harris, Pamela, Erlichman, Charles
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2014
Assuntos:
Endocrine Care
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4010705/
https://ncbi.nlm.nih.gov/pubmed/24606083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2013-3713
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados